8.20
Terns Pharmaceuticals Inc stock is currently priced at $8.20, with a 24-hour trading volume of 1.74M.
It has seen a +2.76% increased in the last 24 hours and a +36.89% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $7.92 pivot point. If it approaches the $8.48 resistance level, significant changes may occur.
Previous Close:
$7.98
Open:
$8.01
24h Volume:
1.74M
Market Cap:
$530.35M
Revenue:
-
Net Income/Loss:
$-90.21M
P/E Ratio:
-6.3566
EPS:
-1.29
Net Cash Flow:
$-67.44M
1W Performance:
+14.69%
1M Performance:
+36.89%
6M Performance:
+26.54%
1Y Performance:
-30.33%
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650 525 5535
Address
1065 East Hillsdale Boulevard, Suite 100, Foster City
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-08-23 | Initiated | BMO Capital Markets | Outperform |
Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
Feb-07-23 | Initiated | UBS | Buy |
Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
Sep-14-21 | Resumed | Goldman | Buy |
Mar-02-21 | Initiated | Cowen | Outperform |
Mar-02-21 | Initiated | Goldman | Buy |
Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Taking a look at what insiders are doing to gauge the Terns Pharmaceuticals Inc (TERN)'s direction – Knox Daily - Knox Daily
Knox Daily
Terns Pharmaceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
The InvestChronicle
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
MarketBeat
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Defense World
Terns Pharmaceuticals (NASDAQ:TERN) Trading 11.5% Higher - MarketBeat
MarketBeat
Great Point Partners LLC Has $8.50 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - MarketBeat
MarketBeat
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Terns Pharmaceuticals Inc (TERN) Net Income 2024
TERN net income (TTM) was -$90.21 million for the quarter ending December 31, 2023, a -49.49% decrease year-over-year.
Terns Pharmaceuticals Inc (TERN) Cash Flow 2024
TERN recorded a free cash flow (TTM) of -$67.44 million for the quarter ending December 31, 2023, a -36.57% decrease year-over-year.
Terns Pharmaceuticals Inc (TERN) Earnings per Share 2024
TERN earnings per share (TTM) was -$1.27 for the quarter ending December 31, 2023, a +30.60% growth year-over-year.
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.
Cap:
|
Volume (24h):